Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial

Micro-Abstract Cisplatin with pemetrexed followed by maintenance pemetrexed and carboplatin with paclitaxel and bevacizumab followed by maintenance bevacizumab, standard first-line therapy for advanced nonsquamous non–small-cell lung cancer, were compared. Quality of life (QoL) at 12 weeks of mainte...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2015-07, Vol.16 (4), p.262-273
Main Authors: Galetta, Domenico, Cinieri, Saverio, Pisconti, Salvatore, Gebbia, Vittorio, Morabito, Alessandro, Borsellino, Nicola, Maiello, Evaristo, Febbraro, Antonio, Catino, Annamaria, Rizzo, Pietro, Montrone, Michele, Misino, Andrea, Logroscino, Antonio, Rizzi, Daniele, Di Maio, Massimo, Colucci, Giuseppe
Format: Article
Language:English
Subjects:
Adult
Advanced NSCLC
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - administration & dosage
Carboplatin - administration & dosage
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Cisplatin - administration & dosage
EQ5D
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Middle Aged
Neoplasm Staging
Paclitaxel - administration & dosage
Pemetrexed - administration & dosage
Pulmonary/Respiratory
Quality of Life
Symptom palliation
Treatment choice
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Cisplatin with pemetrexed followed by maintenance pemetrexed and carboplatin with paclitaxel and bevacizumab followed by maintenance bevacizumab, standard first-line therapy for advanced nonsquamous non–small-cell lung cancer, were compared. Quality of life (QoL) at 12 weeks of maintenance, measured using the EuroQoL 5 Dimensions (EQ5D) Index and EQ5D-visual analogue scale, was the primary end point. QoL did not differ between these regimens. Comorbidities and other factors should help in deciding first-line treatment.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2014.12.002